Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000

Rhea-AI Summary

Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency investment portfolio to USD $5,000,000 through additional purchases of Bitcoin (BTC) and other digital currencies. The Board of Directors-approved investment demonstrates the company's strategic approach to using cryptocurrencies as both an investment vehicle and a hedge against the dollar. The company has established infrastructure to accept cryptocurrency-based financing and execute various transactions, with all digital assets being held by a compliant custodian. Quantum BioPharma maintains flexibility to adjust its cryptocurrency holdings based on market conditions while ensuring full compliance with financial and audit regulations.

Positive

• Total cryptocurrency investment reached significant milestone of USD $5,000,000
• Company establishes infrastructure for cryptocurrency-based financing and transactions
• Strategic diversification of assets as hedge against dollar
• Board of Directors approval shows strong corporate governance and support

Negative

• Exposure to volatile cryptocurrency market poses significant investment risk
• Potential regulatory uncertainties surrounding cryptocurrency holdings
• Deviation from core biopharma business focus into speculative digital assets

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased additional Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. This brings the total amount of BTC and other cryptocurrencies purchased to USD $5,000,000. As previously announced the company will continue to allow for future financing and other transactions to be carried out in cryptocurrency.

This move reflects the company's belief in the potential of Bitcoin (BTC) and other currencies to provide a return on investment for shareholders and to provide some hedge against the dollar. The company is now set up to receive financing in cryptocurrencies as well as executing other types of transactions in cryptocurrencies.

The company is holding all its cryptocurrency with a fully compliant custodian. The company emphasizes that all transactions are and will be fully compliant with all relevant financial and audit regulations, ensuring a secure and legal process.

The Company will continue to monitor market conditions and may increase or decrease its holdings of Bitcoin (BTC) or other cryptocurrencies as it deems appropriate.

About Quantum BioPharma Ltd.

Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.

Forward-Looking Information

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.

Forward-looking information in this press release are based on certain assumptions and expected future events.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.

Contacts:

Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com  
Telephone: (833) 571-1811

Investor Relations
Investor Relations: IR@QuantumBioPharma.com  
General Inquiries: info@QuantumBioPharma.com   

FAQ

How much has Quantum BioPharma (QNTM) invested in Bitcoin and other cryptocurrencies?

Quantum BioPharma has invested a total of USD $5,000,000 in Bitcoin (BTC) and other cryptocurrencies.

Why is Quantum BioPharma (QNTM) investing in cryptocurrencies?

The company is investing in cryptocurrencies as a potential return on investment for shareholders and as a hedge against the dollar, while also enabling cryptocurrency-based financing and transactions.

How does Quantum BioPharma (QNTM) store its cryptocurrency holdings?

The company stores all its cryptocurrency holdings with a fully compliant custodian to ensure security and regulatory compliance.

Will Quantum BioPharma (QNTM) continue to invest in cryptocurrencies?

The company will monitor market conditions and may increase or decrease its cryptocurrency holdings as deemed appropriate.

What types of cryptocurrency transactions can Quantum BioPharma (QNTM) now handle?

The company is set up to receive financing in cryptocurrencies and execute various types of business transactions using digital currencies.